Ayala Pharmaceuticals (NASDAQ:ADXS) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note issued to investors on Sunday. The brokerage set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

ADXS stock opened at $0.03 on Friday. Ayala Pharmaceuticals has a twelve month low of $0.00 and a twelve month high of $1.49. The company has a market cap of $1.15 million, a PE ratio of 0.00 and a beta of 1.62. The business’s 50-day simple moving average is $0.04 and its 200 day simple moving average is $0.06.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.